Targeting Chronic Inflammation
to Treat Neurodegeneration and Inflammatory Diseases by Inhibiting the Activity of the NLRP3 Inflammasome
At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system’s response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
Founded in 2017, our incredible team of scientists has worked tirelessly to bring Halia Therapeutics to the forefront in the field of inflammation drug discovery. We will continue to work relentlessly to translate our work into new medicines for patients.
In The News
David Bearss is featured in Biosphere Magazine
David Bearss’ passion for drug discovery has guided his noteworthy career as a dynamic leader who integrates scientific and business interests to deliver new medicines to patients. That passion is still evident today as he gives back to the industry he loves, making a difference with bold initiatives to improve health and change the face of Utah’s life sciences ecosystem.
Halia’s new lab is featured in the Provo Daily Herald
Halia Therapeutics has a new lab in Lehi and believes it is on the forefront of research to target chronic inflammation to treat neurodegeneration and inflammatory diseases.
Halia Therapeutics to Present at the 17th Annual PAINWeek Conference
Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced they will be presenting new data at the 17th Annual PAINWeek Conference on Thursday, September 7, at 5:30 p.m. PDT/8:30 p.m. EDT.
We Are Experienced in Drug Discovery for Oncology and Neurodegeneration
Our scientists have made fundamental discoveries in the fields of oncology, Alzheimer’s disease, and other neurodegenerative disorders, and we leverage these experiences to identify novel targets to treat these diseases.
Pipeline
NEK7
INHIBITORS
LRRK2
INHIBITORS
DISCOVERY PIPELINE
Discovery | INDEnabling | Phase 1 | Phase 2 |
- Oral Systemic Multiple Indications 90%
- Ophthalmology 50%
- Gastroenterology 50%
- Neuroinflammation 40%
- Dermatology 30%
- Intervertebral Disc Disease 30%
- Parkinson's Disease 50%
- Alzheimer's Disease 50%
- PROTAC Targeting Projects 30%
HT-6184
HT-6184
HT-6258
HT-6283
HT-6515
HT-6153
HT-4253
HT-4403
Next Milestone
PH2 in MDS and
Inflammatory Pain
IND 2024
IND 2024
IND 2024
Pipeline
Contact Us
Corporate Headquarters
3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States
info@haliatx.com | +1 (385) 355-4315